

Raphael Etomar Pollock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2606569/publications.pdf>

Version: 2024-02-01

306
papers

22,131
citations

7251

80
h-index

12638

137
g-index

373
all docs

373
docs citations

373
times ranked

19512
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers. <i>Journal of Surgical Oncology</i> , 2022, 125, 239-245.	0.8	5
2	Targetable Pathways in the Treatment of Retroperitoneal Liposarcoma. <i>Cancers</i> , 2022, 14, 1362.	1.7	11
3	Cancer-Derived Extracellular Vesicles: Their Role in Sarcoma. <i>Life</i> , 2022, 12, 481.	1.1	2
4	ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.. <i>American Journal of Cancer Research</i> , 2022, 12, 1577-1592.	1.4	0
5	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	51
6	Cross-flow microfiltration for isolation, selective capture and release of liposarcoma extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12062.	5.5	24
7	Modern multimodality management of patients with caval leiomyosarcoma: New treatment paradigms and potential molecular insights. <i>Journal of Surgical Oncology</i> , 2021, 123, 1618-1623.	0.8	1
8	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	0.7	14
9	Disease Biology is "King" in Retroperitoneal Liposarcoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 832-834.	0.7	3
10	Resection Status Does Not Impact Recurrence in Well-Differentiated Liposarcoma of the Extremity. <i>American Surgeon</i> , 2021, 87, 000313482110545.	0.4	2
11	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. <i>Journal of Surgical Research</i> , 2020, 245, 577-586.	0.8	3
12	Î-catenin S45F mutation results in apoptotic resistance. <i>Oncogene</i> , 2020, 39, 5589-5600.	2.6	30
13	Multi-Layer Micro-Nanofluidic Device for Isolation and Capture of Extracellular Vesicles Derived From Liposarcoma Cell Conditioned Media. <i>Journal of Microelectromechanical Systems</i> , 2020, 29, 776-782.	1.7	7
14	Extracellular vesicle cross-talk in the liposarcoma microenvironment. <i>Cancer Letters</i> , 2020, 487, 27-33.	3.2	10
15	Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis. <i>BMC Cancer</i> , 2020, 20, 527.	1.1	16
16	A sommelier to guide wine selection and a specialist to manage the sarcoma patient: Barriers to referral and definition of a sarcoma specialist. <i>Journal of Surgical Oncology</i> , 2020, 121, 925-926.	0.8	3
17	Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation. <i>Cancers</i> , 2020, 12, 1040.	1.7	10
18	Neoadjuvant radiation improves margin-negative resection rates in extremity sarcoma but not survival. <i>Journal of Surgical Oncology</i> , 2020, 121, 1249-1258.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Adipose Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1226, 73-86.	0.8	8
20	Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?. <i>Oncoscience</i> , 2020, 7, 10-13.	0.9	2
21	<i>MDM2</i> Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes. <i>Cancer Research</i> , 2019, 79, 4911-4922.	0.4	23
22	Targeted muscle reinnervation in oncologic amputees: Early experience of a novel institutional protocol. <i>Journal of Surgical Oncology</i> , 2019, 120, 348-358.	0.8	69
23	Synchronous recurrence of concurrent colon adenocarcinoma and dedifferentiated liposarcoma. <i>BMJ Case Reports</i> , 2019, 12, e228868.	0.2	4
24	Autophagy inhibition overcomes sorafenib resistance in S45Fâ€mutated desmoid tumors. <i>Cancer</i> , 2019, 125, 2693-2703.	2.0	21
25	Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. <i>Oncologist</i> , 2019, 24, 989-996.	1.9	23
26	Surgery for Abdominal Well-Differentiated Liposarcoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 1.	1.3	29
27	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	2.1	142
28	Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. <i>Journal of Neurosurgery</i> , 2018, 129, 805-814.	0.9	12
29	Retroperitoneal sarcomas: Big tumors that involve more than just â€Getting it Outâ€. <i>Journal of Surgical Oncology</i> , 2018, 117, 5-6.	0.8	2
30	Historical perspectives and future directions in the surgical management of retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 7-11.	0.8	15
31	Multidisciplinary sarcoma care. <i>Current Problems in Surgery</i> , 2018, 55, 517-580.	0.6	2
32	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. <i>Sarcoma</i> , 2018, 2018, 1-9.	0.7	13
33	A Case of Acute Iliocaval Thrombosis in the Setting of a Suprarenal Inferior Vena Cava Saccular Aneurysm. <i>Annals of Vascular Surgery</i> , 2018, 53, 271.e7-271.e10.	0.4	1
34	The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia. <i>Cancer Research</i> , 2018, 78, 6680-6690.	0.4	33
35	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. <i>Journal of Surgical Research</i> , 2018, 231, 248-256.	0.8	2
36	miR-133a function in the pathogenesis of dedifferentiated liposarcoma. <i>Cancer Cell International</i> , 2018, 18, 89.	1.8	13

#	ARTICLE	IF	CITATIONS
37	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4865-4873.	3.2	68
38	Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma. <i>Anticancer Research</i> , 2018, 38, 3535-3542.	0.5	12
39	Surgical management of retroperitoneal sarcoma and opportunities for global collaboration. <i>Chinese Clinical Oncology</i> , 2018, 7, 39-39.	0.4	22
40	Multidisciplinary management of soft tissue sarcoma. <i>Chinese Clinical Oncology</i> , 2018, 7, 34-34.	0.4	1
41	TGF- β^2 and CTGF are Mitogenic Output Mediators of Wnt/ β^2 -Catenin Signaling in Desmoid Fibromatosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 559-565.	0.6	8
42	Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transatlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	2.0	104
43	Autophagy as a potential target for sarcoma treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 40-50.	3.3	19
44	Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression. <i>Cancer Research</i> , 2017, 77, 3846-3856.	0.4	141
45	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	13.5	738
46	Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors. <i>Methods in Molecular Biology</i> , 2017, 1510, 365-374.	0.4	3
47	Pulmonary tumor embolism secondary to soft tissue and bone sarcomas: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2017, 15, 168.	0.8	11
48	Title is missing!. , 2017, , .		4
49	Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates. <i>PLoS ONE</i> , 2017, 12, e0188859.	1.1	10
50	Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. <i>Frontiers in Oncology</i> , 2016, 6, 134.	1.3	2
51	Breast Cancer Genetic Counseling: A Surgeon's Perspective. <i>Frontiers in Surgery</i> , 2016, 3, 4.	0.6	11
52	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgery</i> , 2016, 263, 1002-1009.	2.1	392
53	Patterns of major wound complications following multidisciplinary therapy for lower extremity soft tissue sarcoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 385-391.	0.8	24
54	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	2.0	77

#	ARTICLE	IF	CITATIONS
55	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surgery, 2016, 151, 347.	2.2	40
56	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncology, The, 2016, 17, 671-680.	5.1	318
57	Liposarcoma: molecular targets and therapeutic implications. Cellular and Molecular Life Sciences, 2016, 73, 3711-3718.	2.4	34
58	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Annals of Surgical Oncology, 2016, 23, 3531-3540.	0.7	136
59	Management of Desmoids. Surgical Clinics of North America, 2016, 96, 1015-1030.	0.5	17
60	The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): "Red wine or white". Annals of Surgical Oncology, 2016, 23, 4418-4420.	0.7	15
61	Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis. Oncology and Therapy, 2016, 4, 57-72.	1.0	59
62	Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biology and Therapy, 2016, 17, 129-138.	1.5	9
63	SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clinical Cancer Research, 2016, 22, 1150-1160.	3.2	84
64	HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components. Molecular Cancer Research, 2016, 14, 35-43.	1.5	19
65	NF- κ B functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget, 2016, 7, 23395-23415.	0.8	12
66	An Overview of Chromatin-Regulating Proteins in Cells. Current Protein and Peptide Science, 2016, 17, 401-410.	0.7	68
67	Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer, 2015, 121, 4088-4096.	2.0	64
68	Angiosarcoma: A rare malignancy with protean clinical presentations. Journal of Surgical Oncology, 2015, 111, 941-950.	0.8	18
69	AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer, 2015, 15, 901.	1.1	22
70	Contemporary approaches to sarcoma. Journal of Surgical Oncology, 2015, 111, 489-489.	0.8	0
71	Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer, 2015, 121, 3659-3667.	2.0	17
72	HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS ONE, 2015, 10, e0133302.	1.1	43

#	ARTICLE	IF	CITATIONS
73	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. <i>Sarcoma</i> , 2015, 2015, 1-9.	0.7	48
74	Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for management. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211218.	0.2	6
75	Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. <i>Molecular Cancer</i> , 2015, 14, 55.	7.9	31
76	Raman spectroscopy complements optical coherent tomography in tissue classification and cancer detection. , 2015, , .		1
77	The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. <i>Laboratory Investigation</i> , 2015, 95, 951-961.	1.7	12
78	Accuracy of Preoperative Percutaneous Biopsy for the Diagnosis of Retroperitoneal Liposarcoma Subtypes. <i>Annals of Surgical Oncology</i> , 2015, 22, 1068-1072.	0.7	43
79	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
80	Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. <i>Annals of Surgical Oncology</i> , 2015, 22, 3913-3920.	0.7	56
81	Development of optical sensor for soft tissue sarcoma boundary detection using optical coherence elastography. , 2014, , .		1
82	Assessment of multimodality therapy use for extremity sarcoma in the United States. <i>Journal of Surgical Oncology</i> , 2014, 109, 395-404.	0.8	41
83	Line-scan Raman microscopy complements optical coherence tomography for tumor boundary detection. <i>Laser Physics Letters</i> , 2014, 11, 105602.	0.6	19
84	Imagine a world without cancer. <i>BMC Cancer</i> , 2014, 14, 186.	1.1	12
85	EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. <i>Journal of Pathology</i> , 2014, 232, 308-318.	2.1	62
86	Mesenchymal to epithelial transition in sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 593-601.	1.3	44
87	Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2014, 21, 2499-2505.	0.7	33
88	Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?. <i>Annals of Surgical Oncology</i> , 2014, 21, 2136-2143.	0.7	96
89	Patient-derived xenografts for individualized care in advanced sarcoma. <i>Cancer</i> , 2014, 120, 2006-2015.	2.0	154
90	Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. <i>Leukemia and Lymphoma</i> , 2014, 55, 121-127.	0.6	49

#	ARTICLE	IF	CITATIONS
91	Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. <i>Oncotarget</i> , 2014, 5, 9065-9078.	0.8	16
92	Sarcomas. , 2014, , 453-466.		0
93	Epigenetic Regulators: New Therapeutic Targets for Soft Tissue Sarcoma. <i>Cancer Cell & Microenvironment</i> , 2014, 1, .	0.8	7
94	Lumping, Splitting, and Making Sense: Implications of Soft Tissue Sarcoma Staging for Prognosis, Therapy, and Research. <i>Annals of Surgical Oncology</i> , 2013, 20, 3355-3356.	0.7	0
95	Computational analysis of optical coherence tomography images for the detection of soft tissue sarcomas. <i>Proceedings of SPIE</i> , 2013, , .	0.8	2
96	Quality of Local Treatment or Biology of the Tumor: Which are the Trump Cards for Loco-regional Control of Retroperitoneal Sarcoma?. <i>Annals of Surgical Oncology</i> , 2013, 20, 2111-2113.	0.7	36
97	Uterine Leiomyosarcoma Management, Outcome, and Associated Molecular Biomarkers: A Single Institution's Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2364-2372.	0.7	61
98	Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. <i>Cancer</i> , 2013, 119, 1885-1891.	2.0	35
99	Complex Reconstruction of Desmoid Tumor Resections Does Not Increase Desmoid Tumor Recurrence. <i>Journal of the American College of Surgeons</i> , 2013, 217, 472-480.	0.2	18
100	Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. <i>Stem Cell Research</i> , 2013, 11, 772-781.	0.3	16
101	Long-Term Outcomes in Patients with Radiation-Associated Angiosarcomas of the Breast Following Surgery and Radiotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1267-1274.	0.7	116
102	Combining a focused air-puff system with phase-sensitive optical coherence tomography for the detection of soft-tissue tumors based on elasticity measurement. , 2013, , .		0
103	Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results. <i>Cancers</i> , 2013, 5, 529-549.	1.7	43
104	Lymphotoxin β_2 receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF- κ B activation. <i>Carcinogenesis</i> , 2013, 34, 1105-1114.	1.3	27
105	Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. <i>Journal of Clinical Oncology</i> , 2013, 31, 1649-1655.	0.8	268
106	Three-dimensional computational analysis of optical coherence tomography images for the detection of soft tissue sarcomas. <i>Journal of Biomedical Optics</i> , 2013, 19, 021102.	1.4	31
107	Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. <i>Carcinogenesis</i> , 2013, 34, 1039-1043.	1.3	37
108	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	2.0	162

#	ARTICLE	IF	CITATIONS
109	Localized and metastatic myxoid/round cell liposarcoma. <i>Cancer</i> , 2013, 119, 1868-1877.	2.0	90
110	Soft Tissue Sarcomas. , 2013, , 311-318.		0
111	Extended surgery for retroperitoneal sarcoma: too much surgery for some and not enough for others? <i>Con. Oncology</i> , 2013, 27, 641-2.	0.4	6
112	A Population-Based Study of the Quality of Care in the Diagnosis of Large (≥5 cm) Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 455-461.	0.6	7
113	Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2012, 18, 4633-4645.	3.2	47
114	Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2545-2557.	3.2	44
115	Lymphocyte Composition and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 941-944.	2.1	21
116	Soft Tissue Sarcoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 951-960.	2.3	117
117	Value-Based Health Care. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 497-506.	0.6	14
118	Sarcomas of the breast. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1045-1051.	1.1	20
119	Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC-STBSG. <i>Annals of Surgical Oncology</i> , 2012, 19, 2981-2991.	0.7	212
120	MiR-155 Is a Liposarcoma Oncogene That Targets Casein Kinase-1 α and Enhances β -Catenin Signaling. <i>Cancer Research</i> , 2012, 72, 1751-1762.	0.4	104
121	Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1758-1769.	1.9	41
122	Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance. <i>Cancer Research</i> , 2012, 72, 4724-4732.	0.4	38
123	Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. <i>Modern Pathology</i> , 2012, 25, 1298-1306.	2.9	403
124	Primary Retroperitoneal Tumors. , 2012, , 403-421.		0
125	Noncontact measurement of elasticity for the detection of soft-tissue tumors using phase-sensitive optical coherence tomography combined with a focused air-puff system. <i>Optics Letters</i> , 2012, 37, 5184.	1.7	95
126	Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. <i>Clinical Sarcoma Research</i> , 2012, 2, 25.	2.3	22

#	ARTICLE	IF	CITATIONS
127	Incorporation of Adjuvant Therapy into the Multimodality Management of Gastrointestinal Stromal Tumors of the Stomach in the United States. <i>Annals of Surgical Oncology</i> , 2012, 19, 184-191.	0.7	17
128	Sarcoma metastases to the skin. <i>Cancer</i> , 2012, 118, 2900-2904.	2.0	34
129	Expression of concern. <i>Cancer</i> , 2012, 118, 1173-1173.	2.0	0
130	Surgical Management of Desmoid Tumors. , 2012, , 77-90.		0
131	Epithelioid Sarcoma and Unclassified Sarcoma with Epithelioid Features: Clinicopathological Variables, Molecular Markers, and a New Experimental Model. <i>Oncologist</i> , 2011, 16, 512-522.	1.9	53
132	New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. <i>Drug Resistance Updates</i> , 2011, 14, 52-66.	6.5	46
133	Desmoid Tumor. <i>Annals of Plastic Surgery</i> , 2011, 67, 551-564.	0.5	31
134	Differentiating retroperitoneal liposarcoma tumors with optical coherence tomography. , 2011, , .		0
135	Low-Grade Follicular Lymphoma of the Small Intestine: A Challenge for Management. <i>Seminars in Oncology</i> , 2011, 38, 714-720.	0.8	5
136	Surgery in Retroperitoneal Soft Tissue Sarcoma: A Call for a Consensus Between Europe and North America. <i>Annals of Surgical Oncology</i> , 2011, 18, 2107-2110.	0.7	37
137	Diagnosis, Management, and Outcome of Patients with Dedifferentiated Liposarcoma Systemic Metastasis. <i>Annals of Surgical Oncology</i> , 2011, 18, 3762-3770.	0.7	58
138	Unique patterns of metastases in common and rare types of malignancy. <i>Journal of Surgical Oncology</i> , 2011, 103, 607-614.	0.8	29
139	Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. <i>Cancer</i> , 2011, 117, 380-389.	2.0	35
140	Pleomorphic liposarcoma. <i>Cancer</i> , 2011, 117, 5359-5369.	2.0	92
141	Farewell, with gratitude. <i>Cancer</i> , 2011, 117, 4106-4107.	2.0	0
142	Revealing retroperitoneal liposarcoma morphology using optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2011, 16, 020502.	1.4	16
143	Angiosarcoma. <i>Annals of Surgery</i> , 2010, 251, 1098-1106.	2.1	182
144	Soft Tissue Sarcoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 630-674.	2.3	112

#	ARTICLE	IF	CITATIONS
145	Managing Elderly Soft Tissue Sarcoma Patients—Should Age Drive Treatment?. <i>Annals of Surgical Oncology</i> , 2010, 17, 1725-1726.	0.7	13
146	Platelet-derived growth factor receptor β inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity. <i>Cancer</i> , 2010, 116, 3892-3902.	2.0	19
147	The integrity of authorship. <i>Cancer</i> , 2010, 116, 3986-3987.	2.0	3
148	Neoadjuvant treatment of soft tissue sarcoma: A multimodality approach. <i>Journal of Surgical Oncology</i> , 2010, 101, 327-333.	0.8	28
149	Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. <i>Annals of Oncology</i> , 2010, 21, 1112-1120.	0.6	18
150	An Integrated Study of Aberrant Gene Copy Number and Gene Expression in GIST and LMS. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 171-177.	0.8	7
151	Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. <i>Annals of Oncology</i> , 2010, 21, 397-402.	0.6	117
152	Integrated Proteomics and Genomics Analysis Reveals a Novel Mesenchymal to Epithelial Reverting Transition in Leiomyosarcoma through Regulation of Slug. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 2405-2413.	2.5	56
153	Protocol for the Examination of Specimens From Patients With Tumors of Soft Tissue. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, e31-e39.	1.2	33
154	Gene Therapy for Sarcoma. , 2010, , 251-268.		0
155	Increased Vascular Endothelial Growth Factor-C Expression Is Insufficient to Induce Lymphatic Metastasis in Human Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2009, 15, 2637-2646.	3.2	14
156	IFN Regulatory Factor 8 Sensitizes Soft Tissue Sarcoma Cells to Death Receptor-Initiated Apoptosis via Repression of FLICE-like Protein Expression. <i>Cancer Research</i> , 2009, 69, 1080-1088.	0.4	32
157	Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1157-1168.	1.9	83
158	New Editor-in-Chief named for <i>Cancer Cytopathology</i> . <i>Cancer</i> , 2009, 115, 1360-1360.	2.0	0
159	Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. <i>Cancer</i> , 2009, 115, 2971-2979.	2.0	27
160	A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. <i>Annals of Surgical Oncology</i> , 2009, 16, 910-919.	0.7	166
161	Establishing Prognosis in Retroperitoneal Sarcoma: A New Histology-Based Paradigm. <i>Annals of Surgical Oncology</i> , 2009, 16, 667-675.	0.7	74
162	Outcome of Locally Recurrent and Metastatic Angiosarcoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 2502-2509.	0.7	64

#	ARTICLE	IF	CITATIONS
163	Complete Soft Tissue Sarcoma Resection is a Viable Treatment Option for Select Elderly Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 2579-2586.	0.7	64
164	Genetic aberrations in soft tissue leiomyosarcoma. <i>Cancer Letters</i> , 2009, 275, 1-8.	3.2	96
165	Resection of Pulmonary and Extrapulmonary Sarcomatous Metastases Is Associated With Long-Term Survival. <i>Annals of Thoracic Surgery</i> , 2009, 88, 877-885.	0.7	137
166	Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2009, 15, 3472-3483.	3.2	70
167	Multifocality in Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2009, 249, 137-142.	2.1	108
168	Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome. <i>Annals of Surgery</i> , 2009, 249, 1014-1022.	2.1	254
169	Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. <i>In Vivo</i> , 2009, 23, 903-9.	0.6	23
170	Surgical oncology: Training for multidisciplinary cancer care. <i>Journal of Surgical Oncology</i> , 2008, 97, 3-4.	0.8	2
171	Board certification in surgical oncology: Does it make sense?. <i>Journal of Surgical Oncology</i> , 2008, 98, 1-2.	0.8	0
172	The role of surgical margin status in retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2008, 98, 607-610.	0.8	89
173	Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. <i>Cancer</i> , 2008, 112, 1821-1826.	2.0	39
174	New content highlighted for Cancer. <i>Cancer</i> , 2008, 113, 4-4.	2.0	0
175	Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. <i>Cancer</i> , 2008, 113, 411-418.	2.0	13
176	The seminal role of Cancer in our understanding of sarcoma. <i>Cancer</i> , 2008, 113, 1969-1979.	2.0	2
177	Happy 60 th birthday, Cancer!. <i>Cancer</i> , 2008, 113, 1717-1717.	2.0	0
178	Genetic aberrations of gastrointestinal stromal tumors. <i>Cancer</i> , 2008, 113, 1532-1543.	2.0	72
179	Excellent Local Control Rates and Distinctive Patterns of Failure in Myxoid Liposarcoma Treated With Conservation Surgery and Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 760-765.	0.4	83
180	Surgical Oncology at the Crossroads: the Future is Now. <i>Annals of Surgical Oncology</i> , 2008, 15, 661-669.	0.7	2

#	ARTICLE	IF	CITATIONS
181	Resectable Well-Differentiated versus Dedifferentiated Liposarcomas: Two Different Diseases Possibly Requiring Different Treatment Approaches. <i>Annals of Surgical Oncology</i> , 2008, 15, 1585-1593.	0.7	109
182	New Perspectives for Staging and Prognosis in Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 2739-2748.	0.7	126
183	Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. <i>Molecular Oncology</i> , 2008, 2, 161-163.	2.1	19
184	Specific Mutations in the β -Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors. <i>American Journal of Pathology</i> , 2008, 173, 1518-1527.	1.9	417
185	Combined Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor Blockade with Chemotherapy for Treatment of Local, Uterine, and Metastatic Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2008, 14, 5466-5475.	3.2	31
186	Identification and Functional Characterization of the Human <i>Glutathione S-Transferase P1</i> Gene as a Novel Transcriptional Target of the <i>p53</i> Tumor Suppressor Gene. <i>Molecular Cancer Research</i> , 2008, 6, 843-850.	1.5	50
187	A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4471-4476.	3.3	72
188	Midkine Enhances Soft-Tissue Sarcoma Growth: A Possible Novel Therapeutic Target. <i>Clinical Cancer Research</i> , 2008, 14, 5033-5042.	3.2	33
189	Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth <i>In vitro</i> and <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2008, 14, 2785-2795.	3.2	37
190	Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45 \pm . <i>Cancer Research</i> , 2008, 68, 2895-2903.	0.4	52
191	Value-Based Health Care. <i>Annals of Surgery</i> , 2008, 248, 510-516.	2.1	13
192	Challenges in Surgical Management of Abdominal Pain in the Neutropenic Cancer Patient. <i>Annals of Surgery</i> , 2008, 248, 104-109.	2.1	54
193	Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3414-3419.	3.3	144
194	Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 7314-7321.	3.2	90
195	Optimizing Treatment of Desmoid Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 1785-1791.	0.8	255
196	Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1650-1660.	1.9	116
197	Soft Tissue Sarcoma Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 364.	2.3	38
198	Long-term Results of Prospective Trial of Surgery Alone With Selective Use of Radiation for Patients With T1 Extremity and Trunk Soft Tissue Sarcomas. <i>Annals of Surgery</i> , 2007, 246, 675-682.	2.1	125

#	ARTICLE	IF	CITATIONS
199	Surgical oncology at the crossroads: which way forward?. <i>Lancet Oncology</i> , The, 2007, 8, 182-183.	5.1	3
200	Current concepts in multimodality therapy for retroperitoneal sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 159-168.	1.1	28
201	Periosteal margin in soft-tissue sarcoma. <i>Cancer</i> , 2007, 109, 598-602.	2.0	38
202	High prevalence of p53 exon 4 mutations in soft tissue sarcoma. <i>Cancer</i> , 2007, 109, 2323-2333.	2.0	39
203	Retroperitoneal soft tissue sarcoma: An analysis of radiation and surgical treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 158-163.	0.4	143
204	Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1124-1129.	0.4	72
205	Long-Term Outcomes for Synovial Sarcoma Treated With Conservation Surgery and Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1173-1180.	0.4	81
206	Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. <i>Gene Therapy</i> , 2007, 14, 671-681.	2.3	16
207	Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis. <i>Annals of Surgical Oncology</i> , 2007, 14, 2309-2318.	0.7	58
208	Career Satisfaction, Practice Patterns and Burnout among Surgical Oncologists: Report on the Quality of Life of Members of the Society of Surgical Oncology. <i>Annals of Surgical Oncology</i> , 2007, 14, 3043-3053.	0.7	257
209	Splenectomy in Patients with Chronic Myeloid Leukemia or Myeloproliferative Diseases: Outcomes, Complications and Prognostic Implications.. <i>Blood</i> , 2007, 110, 2553-2553.	0.6	0
210	Long-Term Results of Two Prospective Trials of Preoperative External Beam Radiotherapy for Localized Intermediate- or High-Grade Retroperitoneal Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2006, 13, 508-517.	0.7	234
211	The Effect of Preoperative Radiotherapy and Reconstructive Surgery on Wound Complications after Resection of Extremity Soft-Tissue Sarcomas. <i>Annals of Surgical Oncology</i> , 2006, 13, 1209-1215.	0.7	94
212	Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib. <i>Annals of Surgical Oncology</i> , 2006, 14, 14-24.	0.7	220
213	Staging Soft Tissue Sarcoma: Evolution and Change. <i>Ca-A Cancer Journal for Clinicians</i> , 2006, 56, 282-291.	157.7	107
214	Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2006, 107, 1898-1908.	2.0	37
215	Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance. <i>Cancer Research</i> , 2006, 66, 8770-8778.	0.4	72
216	Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver. <i>Archives of Surgery</i> , 2006, 141, 537.	2.3	156

#	ARTICLE	IF	CITATIONS
217	Wild-type p53 Inhibits Nuclear Factor- κ B-Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis. <i>Molecular Cancer Research</i> , 2006, 4, 803-810.	1.5	63
218	Molecular Diagnosis of Sarcomas: Chromosomal Translocations in Sarcomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1199-1207.	1.2	85
219	Gene therapy with E2F-1 up-regulates the protein kinase PKR and inhibits growth of leiomyosarcoma in vivo. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1710-1716.	1.9	20
220	Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. <i>Cancer</i> , 2005, 103, 830-838.	2.0	81
221	Angiosarcoma of the breast. <i>Cancer</i> , 2005, 104, 2682-2688.	2.0	183
222	Extremity soft tissue sarcoma: Evidence-based multidisciplinary management. <i>Journal of Surgical Oncology</i> , 2005, 90, 10-13.	0.8	20
223	Transcriptional Repression of Protein Kinase ζ via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation. <i>Journal of Biological Chemistry</i> , 2005, 280, 4825-4833.	1.6	48
224	Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. <i>Human Molecular Genetics</i> , 2005, 14, 1785-1794.	1.4	27
225	Soft tissue sarcoma clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 158-94.	2.3	15
226	A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. <i>Clinical Cancer Research</i> , 2005, 11, 217-25.	3.2	191
227	Phase I Trial of Preoperative Doxorubicin-Based Concurrent Chemoradiation and Surgical Resection for Localized Extremity and Body Wall Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 3375-3380.	0.8	74
228	Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. <i>Journal of Clinical Oncology</i> , 2004, 22, 4567-4574.	0.8	149
229	A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2004, 64, 5913-5919.	0.4	334
230	Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2004, 127, 1366-1372.	0.4	46
231	Soft Tissue Sarcomas. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 94-109.	157.7	468
232	Upper Extremity Reconstruction Following Resection of Soft Tissue Sarcomas: A Functional Outcomes Analysis. <i>Annals of Surgical Oncology</i> , 2004, 11, 921-927.	0.7	39
233	A brief note about a new series!. <i>Cancer</i> , 2004, 100, 2047-2047.	2.0	0
234	Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2004, 239, 818-827.	2.1	1,553

#	ARTICLE	IF	CITATIONS
235	Platelet Kinetics and Decreased Transfusion Requirements After Splenectomy for Hematologic Malignancy. <i>Annals of Surgery</i> , 2004, 240, 852-857.	2.1	8
236	Increasing the pool of academically oriented African-American medical and surgical oncologists. <i>Cancer</i> , 2003, 97, 329-334.	2.0	33
237	Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy. <i>Cancer</i> , 2003, 97, 2530-2543.	2.0	591
238	Surgical margins and resection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. <i>Cancer</i> , 2003, 97, 2544-2553.	2.0	179
239	Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: A retrospective comparative evaluation of disease outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 482-488.	0.4	127
240	Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: Analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 739-747.	0.4	121
241	Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. <i>American Journal of Surgery</i> , 2003, 186, 665-669.	0.9	130
242	Phase I Trial of Preoperative Concurrent Doxorubicin and Radiation Therapy, Surgical Resection, and Intraoperative Electron-Beam Radiation Therapy for Patients With Localized Retroperitoneal Sarcoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3092-3097.	0.8	141
243	Preoperative Predictors of Survival After Resection of Small Hepatocellular Carcinomas. <i>Annals of Surgery</i> , 2002, 235, 722-731.	2.1	170
244	Treatment and outcome of patients with intracystic papillary carcinoma of the breast. <i>American Journal of Surgery</i> , 2002, 184, 364-368.	0.9	132
245	Extrasosseous Osteosarcoma: Response to Treatment and Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 521-527.	0.8	90
246	Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas. <i>Cancer</i> , 2002, 94, 197-204.	2.0	48
247	Soft tissue sarcoma of the upper extremity. <i>Cancer</i> , 2002, 94, 2256-2264.	2.0	100
248	Tumor specific gene expression profiles in human leiomyosarcoma. <i>Cancer</i> , 2002, 94, 2069-2075.	2.0	34
249	Tumor volume as a prognostic factor for sarcomatosis. <i>Cancer</i> , 2002, 94, 2441-2446.	2.0	52
250	Surgical management of soft tissue sarcomas of the hand and foot. <i>Cancer</i> , 2002, 95, 852-861.	2.0	110
251	Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. <i>Cancer</i> , 2002, 95, 1120-1126.	2.0	109
252	Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. <i>Annals of Surgical Oncology</i> , 2002, 9, 256-265.	0.7	112

#	ARTICLE	IF	CITATIONS
253	Long-term complications associated with breast-conservation surgery and radiotherapy. <i>Annals of Surgical Oncology</i> , 2002, 9, 543-549.	0.7	223
254	Steps toward mapping the human vasculature by phage display. <i>Nature Medicine</i> , 2002, 8, 121-127.	15.2	557
255	Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. , 2002, 9, 256.		5
256	Long-term complications associated with breast-conservation surgery and radiotherapy. , 2002, 9, 543.		12
257	Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. <i>Cancer Research</i> , 2002, 62, 2034-42.	0.4	73
258	Epithelioid sarcoma: results of conservative surgery and radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 384-391.	0.4	81
259	Alveolar soft part sarcoma. <i>Cancer</i> , 2001, 91, 585-591.	2.0	305
260	Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. <i>Cancer</i> , 2001, 92, 863-868.	2.0	60
261	Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. <i>Cancer</i> , 2001, 92, 1556-1566.	2.0	64
262	Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. , 2001, 92, 1556.		1
263	Primary treatment of cystosarcoma phyllodes of the breast. <i>Cancer</i> , 2000, 89, 1502-1511.	2.0	320
264	Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. <i>Cancer Gene Therapy</i> , 2000, 7, 422-429.	2.2	25
265	Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2000, 7, 435-440.	0.7	26
266	Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2000, 7, 656-664.	0.7	38
267	Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 3378-3383.	0.8	84
268	Primary treatment of cystosarcoma phyllodes of the breast. , 2000, 89, 1502.		2
269	Long-Term Outcome of Patients With American Joint Committee on Cancer Stage IIB Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 1999, 17, 2772-2772.	0.8	75
270	Reliable Establishment of Human Sarcoma Xenografts in the Nude Rat. <i>Sarcoma</i> , 1999, 3, 129-133.	0.7	4

#	ARTICLE	IF	CITATIONS
271	Training for Careers in Academic Surgical Oncology: The Future Is Bright. <i>Annals of Surgical Oncology</i> , 1999, 6, 517-518.	0.7	1
272	Staging and prognostic factors in soft tissue sarcoma. <i>Seminars in Radiation Oncology</i> , 1999, 9, 307-314.	1.0	43
273	Patterns of recurrence in extremity liposarcoma. , 1999, 85, 85-92.		119
274	Role of radiotherapy in sarcoma of the breast – a retrospective review of the M.D. Anderson experience. <i>Radiotherapy and Oncology</i> , 1999, 52, 173-178.	0.3	107
275	Laparoscopic splenectomy in patients with hematologic malignancies. <i>American Journal of Surgery</i> , 1999, 178, 530-535.	0.9	57
276	Hemangiopericytoma: A 20-year single-institution experience. <i>Annals of Surgical Oncology</i> , 1998, 5, 350-355.	0.7	117
277	Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection ¹¹ This study was sponsored in part by a grant from SmithKline Beecham Laboratories. Cefonicid was provided by SmithKline Beecham Laboratories, and patients were not charged for the single preoperative dose of cefonicid or for any services associated with administration of the antibiotic or placebo. <i>American Journal of Surgery</i> , 1998, 176, 238-243.	0.9	54
278	Limb-salvage strategies to optimize quality of life: the M.D. Anderson Cancer Center experience. <i>Ca-A Cancer Journal for Clinicians</i> , 1997, 47, 226-238.	157.7	25
279	Treatment of the patient with lung metastases. <i>Current Problems in Surgery</i> , 1996, 33, 881-952.	0.6	11
280	Malignant fibrous histiocytoma in children. <i>Journal of Pediatric Surgery</i> , 1996, 31, 1080-1083.	0.8	34
281	The National Cancer Data Base report on soft tissue sarcoma. <i>Cancer</i> , 1996, 78, 2247-2257.	2.0	108
282	Human peri-tumoral and lung fibroblasts produce paracrine motility factors for recently established human sarcoma cell strains. <i>International Journal of Cancer</i> , 1995, 62, 585-592.	2.3	15
283	Expression of 72 kDa and 92 kDa type IV collagenases from human giant-cell tumor of bone. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 420-426.	1.7	25
284	Soft Tissue Sarcomas of the Extremities: Continuing Challenges for a Multidisciplinary Team. <i>Cancer Investigation</i> , 1995, 13, 137-138.	0.6	4
285	Ethics of Research Training for NIH T32 Surgical Investigators. <i>Journal of Surgical Research</i> , 1995, 58, 247-251.	0.8	13
286	Myofibroblastoma of the Axilla. <i>Ultrastructural Pathology</i> , 1995, 19, 265-268.	0.4	6
287	Molecular determinants of soft tissue sarcoma proliferation. <i>Journal of Surgical Oncology</i> , 1994, 10, 315-322.	1.4	8
288	Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. <i>Cancer</i> , 1994, 73, 1652-1659.	2.0	235

#	ARTICLE	IF	CITATIONS
289	Diagnosing intramuscular myxoma by fine-needle aspiration: A multidisciplinary approach. Diagnostic Cytopathology, 1994, 11, 255-261.	0.5	43
290	Immediate versus delayed free-tissue transfer salvage of the lower extremity in soft tissue sarcoma patients. Annals of Surgical Oncology, 1994, 1, 11-17.	0.7	38
291	Comparison of charges related to radiotherapy for soft-tissue sarcomas treated by preoperative external-beam irradiation versus interstitial implantation. Annals of Surgical Oncology, 1994, 1, 415-422.	0.7	38
292	Risk of Dissemination of Cancer to Flap Donor Sites During Immediate Reconstructive Surgery. Annals of Plastic Surgery, 1994, 33, 573-575.	0.5	10
293	Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer, 1993, 72, 375-380.	2.0	60
294	Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas Implications for Surgical Management and Staging. Annals of Surgery, 1992, 215, 68-77.	2.1	369
295	Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer, 1992, 69, 1334-1341.	2.0	200
296	Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer, 1992, 69, 2098-2103.	2.0	163
297	Surgical stress impairs natural killer cell programming of tumor for lysis in patients with sarcomas and other solid tumors. Cancer, 1992, 70, 2192-2202.	2.0	96
298	A case-control comparison of durability and cost between implanted reservoir and percutaneous catheters in cancer patients. Journal of Surgical Research, 1991, 51, 377-381.	0.8	18
299	Preoperative Chemotherapy for Soft-tissue Sarcomas of the Extremities. Annals of Surgery, 1990, 211, 476-481.	2.1	122
300	Lytic units reconsidered: Pitfalls in calculation and usage. Journal of Clinical Laboratory Analysis, 1990, 4, 274-282.	0.9	40
301	Cancer-induced immunosuppression: Implications for therapy?. Journal of Surgical Oncology, 1989, 5, 414-419.	1.4	58
302	A surgical oncology perspective on AIDS. Journal of Surgical Oncology, 1985, 1, 153-160.	1.4	3
303	Principles of cancer staging. , 0, , 34-39.		8
304	Post-transplantation lymphoproliferative disease. , 0, , 809-811.		0
305	Level of evidence, guidelines and standards. , 0, , 12-22.		0
306	The Role of AKT in Soft Tissue Sarcoma: Review and Insights. Molecular Cancer Research, 0, , .	1.5	0